BI-1206 is a recombinant antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). It inhibits CD20 internalization induced by Rituximab, whether used alone or in combination with drugs such as Ibrutinib, Venetoclax, and CHOP. BI-1206 can enhance or restore the activity of Rituximab or other anti-CD20 monoclonal antibodies and demonstrates cytolytic activity against malignant B cells. BI-1206 is applicable in research on cancers such as mantle cell lymphoma (MCL).

BI-1206 (5 μg/mL, 0-5 hours) effectively blocks Rituximab (5 μg/mL)-induced CD20 internalization in JeKo-1 cells, as well as Rituximab-based induction when combined with Ibrutinib, Venetoclax, or CHOP.

BI-1206, administered at 10 mg/kg via intravenous injection twice weekly, effectively inhibits tumor growth in ibrutinib-venetoclax dual-resistant MCL PDX (PDX-A) NSG mouse models. When combined with rituximab, it suppresses tumor progression in rituximab-ibrutinib-CAR T triple-resistant MCL PDX (PDX-B) NSG mouse models. The combination of BI-1206 with ibrutinib or venetoclax in NSG mouse models results in enhanced efficacy and prolonged survival over 14 days. Additionally, BI-1206, in combination with venetoclax, exhibits superior antitumor activity and extends survival compared to any single or dual regimen in ibrutinib-rituximab-venetoclax triple-resistant MCL PDX (PDX-C) mouse models.

Human

Monoclonal

Unconjugated